Default company panoramic image
3c7e92d3 7d3e 4276 ac3e 92cc1871cf50

Alzeca Biosciences

Alzeca Biosciences is developing a proprietary imaging agent to diagnose Alzheimer's Disease at the earliest stages.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Founded January 2011
  • Employees 6
  • Website

Company Summary

Alzeca Biosciences is developing ADx, an imaging agent used to detect early stage Alzheimer's Disease. Alzeca's primary goal is to diagnose Alzheimer's early enough, where lifestyle changes (diet, exercise) and therapeutics can still be beneficial. A second benefit of the ADx platform is to more effectively monitor the effectiveness of therapies under development, while enabling more accurate screening of Alzheimer's patients in drug trials.


  • Default avatar
    Robin Mansukhani

    Previous venture capital, I Banking, and start-up biotech experience. Frequent speaker on entrepreneurship, life sciences, and education (including TED). B.S. in Biochemistry from Case Western Reserve University.

  • Default avatar
    Ananth Annapragada
    Chief Scientific Advisor

    Director of Radiology, Texas Children's Hospital in Houston. Serial entrepreneur with 3 previous start-ups spun out from his lab. >$35M raised for previous start-ups.

  • Default avatar
    Jason Eriksen
    Chief Technical Officer

    Co-inventor of Alzeca technology. Ph.D in Neuroscience and previous drug development experience. Post doc from Mayo Clinic.

  • Default avatar
    Steve Cook
    Board Member

    CEO, Fieldstone Partners -- Houston based merchant bank. MBA, Harvard University.


  • Default avatar
    Ewing & Jones, Benesch Friedlander
    Default avatar

Previous Investors

  • Default avatar
    Central Texas Angel Network, Fieldstone Partners
    Default avatar
    Angel Investors, Non dilutive government and foundation grants